Galectins and urological cancer

Journal of Cellular Biochemistry

Volumn 91, Issue 1, 2004, Pages 118-124

  Oka, Natsuo ^a   Takenaka, Yukinori ^a   Raz, Avraham ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Galectins; Urological cancer

Indexed keywords

BETA GALACTOSIDE; GALECTIN; GLYCOPROTEIN;

APOPTOSIS; CANCER GROWTH; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; URINARY TRACT CANCER; BLADDER; FEMALE; KIDNEY; MALE; METABOLISM; PROSTATE;

FEMALE; GALECTINS; HUMANS; KIDNEY; MALE; PROSTATE; URINARY BLADDER; UROLOGIC NEOPLASMS;

EID: 3242791922     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.10663     Document Type: Review

References (72)

1. Altman E, Harrison BA, Latta RK, Lee KK, Kelly JF, Thibault P. 2001. Galectin-3-mediated adherence of Proteus mirabilis to Madin-Darby canine kidney cells. Biochem Cell Biol 79:783-788.
2. Avni O, Pur Z, Yefenof E, Baniyash M. 1998. Complement receptor 3 of macrophages is associated with galectin-1-like protein. J Immunol 160:6151-6158.
3. Bao Q, Hughes RC. 1995. Galectin-3 expression and effects on cyst enlargement and tubulogenesis in kidney epithelial MDCK cells cultured in three-dimensional matrices in vitro. J Cell Sci 108:2791-2800.
4. Barondes SH, Cooper DN, Gitt MA, Leffler H. 1994. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 269:20807-20810.
5. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, Vecchione A, Tecce R, Larsson O, Thyroid Cancer Study Group. 2001. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357:1644-1650.
6. Castronovo V, Van Den Brule FA, Jackers P, Clausse N, Liu FT, Gillet C, Sobel ME. 1996. Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 179:43-48.
7. Choufani G, Nagy N, Saussez S, Marchant H, Bisschop P, Burchert M, Danguy A, Louryan S, Salmon I, Gahius HJ, Kiss R, Hassid S. 1999. The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer 86:2353-2363.
8. Cindolo L, Benvenuto G, Salvatore P, Pero R, Salvatore G, Mirone V, Prezioso D, Altieri V, Bruni CB, Chiariotti L. 1999. Galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas. Int J Cancer 84: 39-43.
9. Danguy A, Camby I, Kiss R. 2002. Galectins and cancer. Biochim Biophys Acta 1572:285-293.
10. Danguy A, Rorive S, Decaestecker C, Bronckart Y, Kaltner H, Hadari YR, Goren R, Zich Y, Petein M, Salmon I, Gabius HJ, Kiss R. 2001. Immunohistochemical profile of galectin-8 expression in benign and malignant tumors of epithelial, mesenchymatous and adipous origins, and the nervous system. Histol Histopathol 16:861-868.
11. Demetriou M, Granovsky M, Quaggin S, Dennis JW. 2001. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409:733-739.
12. Dettin L, Rubinstein N, Aoki A, Rabinovich GA, Maldonado CA. 2003. Regulated expression and ultrastructural localization of galectin-1, a proapoptotic beta-galactoside-binding lectin, during spermatogenesis in rat testis. Biol Reprod 68:51-59.
13. Dunphy JL, Barcham GJ, Bischof RJ, Young AR, Nash A, Meeusen EN. 2002. Isolation and characterization of a novel eosinophil-specific galectin released into the lungs in response to allergen challenge. J Biol Chem 277: 14916-14924.
14. Ellerhorst J, Nguyen T, Cooper DN, Estrov Y, Lotan D, Lotan R. 1999. Induction of differentiation and apoptosis in the prostate cancer cell line LNCaP by sodium butyrate and galectin-1. Int J Oncol 14:225-232.
15. Ellerhorst JA, Stephens LC, Nguyen T, Xu XC. 2002. Effects of galectin-3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP. Prostate 50:64-70.
16. Francois C, Van Velthoven R, De Lathouwer O, Moreno C, Peltier A, Kaltner H, Salmon I, Gabius HJ, Danguy A, Decaestecker C, Kiss R. 1999. Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas. Am J Clin Pathol 112:194-203.
17. Glinsky VV, Huflejt ME, Glinsky GV, Deutscher SL, Quinn TP. 2000. Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on beta-galactoside- mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells. Cancer Res 60:2584-2815.
18. Gu M, Wang W, Song WK, Cooper DN, Kaufman SJ. 1994. Selective modulation of the interaction of alpha 7 beta 1 integrin with fibronectin and laminin by L-14 lectin during skeletal muscle differentiation. J Cell Sci 107: 175-181.
19. Hadari YR, Arbel-Goren R, Levy Y, Amsterdam A, Alon R, Zakut R, Zick Y. 2000. Galectin-8 binding to integrins inhibits cell adhesion and induces apoptosis. J Cell Sci 113:2385-2397.
20. Hikita C, Vijayakumar S, Takito J, Erdjument Bromage H, Tempst P, Al Awqati Q. 2000. Induction of terminal differentiation in epithelial cells requires polymerization of hensin by galectin-3. J Cell Biol 151:1235-1246.
21. Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, Liu FT. 1999. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 81:519-526.
22. Hughes RC. 2001. Galectins as modulators of cell adhesion. Biochimie 83:667-676.
23. Idikio H. 1998. Galectin-3 expression in human breast carcinoma: Correlation with cancer histologic grade. Int J Oncol 12:1287-1290.
24. Inohara H, Raz A. 1994. Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J 11:527-532.
25. Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A, Kubo T. 1999. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 85:2475-2484.
26. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. 2000. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 6:1389-1393.
27. John CM, Leffler H, Kahl-Knutsson B, Svensson I, Jarvis GA. 2003. Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res 9:2374-2383.
28. Karsten U. 1997. Novel alphaGalNAc containing glycans on cytokeratins are recognized in vitro by galectins with type II carbohydrate recognition domains. J Cell Sci 110: 1585-1596.
29. Liu FT, Patterson RJ, Wang JL. 2002. Intracellular functions of galectins. Biochim Biophys Acta 1572:263-273.
30. Lotan R, Ito H, Yasui W, Yokozaki H, Lotan D, Tahara E. 1994. Expression of a 31-kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer 56:474-480.
31. Lotz MM, Andrews CW, Jr., Korzelius CA, Lee EC, Steele GD, Jr., Clarke A, Mercurio AM. 1993. Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA 90:3466-3470.
32. Lurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Lacobelli S. 2000. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 6:1389-1393.
33. Ma YQ, Geng JG. 2002. Obligatory requirement of sulfation for P-selectin binding to human salivary gland carcinoma Acc-M cells and breast carcinoma ZR-75-30 cells. J Immunol 168:1690-1696.
34. Menon RP, Strom M, Hughes RC. 2000. Interaction of a novel cysteine and histidine-rich cytoplasmic protein with galectin-3 in a carbohydrate-independent manner. FEBS Lett 470:227-313.
35. Nagy N, Bronckart Y, Camby I, Legendre H, Lahm H, Kaltner H, Hadari Y, Van Ham P, Yeaton P, Pector JC, Zick Y, Salmon I, Danguy A, Kiss R, Gabius HJ. 2002. Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut 50:392-401.
36. Nangia Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A. 2000. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 156: 899-909.
37. Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, Raz A. 2002. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 94:1854-1862.
38. Nishiyama J, Kobayashi S, Ishida A, Nakabayashi I, Tajima O, Miura S, Katayama M, Nogami H. 2000. Upregulation of galectin-3 in acute renal failure of the rat. Am J Pathol 157:815-823.
39. Ochieng J. 2001. Galectin-3 mediates the endocytosis of beta-1 integrins by breast carcinoma cells. Biochem Biophys Res Commun 289:845-850.
40. Ohannesian DW, Lotan D, Lotan R. 1994. Concomitant increases in galectin-1 and its glycoconjugate ligands (carcinoembryonic antigen, lamp-1, and lamp-2) in cultured human colon carcinoma cells by sodium butyrate. Cancer Res 54(22):5992-6000.
41. Ohannesian DW, Lotan D, Thomas P, Jessup JM, Fukuda M, Gabius HJ, Lotan R. 1995. Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res 55:2191-2199.
42. Pacis RA, Pilat MJ, Pienta KJ, Wojno K, Raz A, Hogan V, Cooper CR. 2000. Decreased galectin-3 expression in prostate cancer. Prostate 44:118-123.
43. Park JWW, Voss PG, Grabski S, Wang JL, Patterson RJ. 2001. Association of galectin-1 and galectin-3 with Gemin4 in complexes containing the SMN protein. Nucleic Acids Res 29:3595-3602.
44. Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y. 2001. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 20: 7486-7493.
45. Perillo NL, Marcus ME, Baum LG. 1998. Galectins: Versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 76:402-412.
46. Pienta KJ, Naik H, Akhtar A, Yamazaki K, Replogle TS, Lehr J, Donat TL, Tait L, Hogan V, Raz A. 1995. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 87:348-353.
47. Platt D, Raz A. 1992. Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin. J Natl Cancer Inst 84:438-442.
48. Probstmeier R, Montag D, Schachner M. 1995. Galectin-3, a beta-galactoside-binding animal lectin, binds to neural recognition molecules. J Neurochem 64:2465-2472.
49. Pugliese G, Pricci F, Leto G, Amadio L, Iacobini C, Romeo G, Lenti L, Sale P, Gradini R, Liu FT, Di Mario U. 2000. The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression. Diabetes 49:1249-1257.
50. Pugliese G, Pricci F, Iacobini C, Leto G, Amadio L, Barsotti P, Frigeri L, Hsu DK, Vlassara H, Liu FT, Di Mario U. 2001. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J 15:2471-2479.
51. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Fay MP, Feuer EJ, Edwards BK. 2003. SEER Cancer Stastitics Review, 1975-2000, http://seer.cancer.gov/csr/1975-2000
52. Rosenberg I, Cherayil BJ, Isselbacher KJ, Pillai S. 1991. Mac-2-binding glycoproteins. Putative ligands for a cytosolic beta-galactoside lectin. J Biol Chem 266:18731-18736.
53. Sasaki S, Bao Q, Hughes RC. 1999. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. J Pathol 187:481-489.
54. Sato S, Hughes RC. 1992. Binding specificity of a baby hamster kidney lectin for H type I and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin. J Biol Chem 267:6983-6990.
55. Schoeppner HL, Raz A, Ho SB, Bresalier RS. 1995. Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 75: 2818-2826.
56. Schwarz G, Jr., Remmelink M, Decaestecker C, Gielen I, Budel V, Burchert M, Darro F, Danguy A, Gabius HJ, Salmon I, Kiss R. 1999. Galectin fingerprinting in tumor diagnosis. Differential expression of galectin-3 and galectin-3 binding sites, but not galectin-1, in benign vs. malignant uterine smooth muscle tumors. Am J Clin Pathol 111:623-631.
57. Seve AP, Hadj-Sahraoui Y, Felin M, Doyennette-Moyne MA, Aubery M, Hubert J. 1994. Evidence that lactose binding to CBP35 disrupts its interaction with CBP70 in isolated HL60 cell nuclei. Exp Cell Res 213:191-197.
58. Shimamura T, Sakamoto M, Ino Y, Shimada K, Kosuge T, Sato Y, Tanaka K, Sekihara H, Hirohashi S. 2002. Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res 8:2570-2575.
59. Su ZZ, Lin J, Shen R, Fisher PE, Goldstein NI, Fisher PB. 1996. Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family. Proc Natl Acad Sci USA 93:7252-7257.
60. Symons A, Cooper DN, Barclay AN. 2000. Characterization of the interaction between galectin-1 and lymphocyte glycoproteins CD45 and Thy-1. Glycobiology 10:559-563.
61. Timmons PM, Rigby PW, Poirier F. 2002. The murine seminiferous epithelial cycle is pre-figured in the Sertoli cells of the embryonic testis. Development 129:635-647.
62. Tsuchiyama Y, Wada J, Zhang H, Morita Y, Hiragushi K, Hida K, Shikata K, Yamamura M, Kanwar YS, Makino H. 2000. Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats. Kidney Int 58:1941-1952.
63. Van den Brule FA, Waltregny D, Liu FT, Castronovo V. 2000. Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 89:361-367.
64. Van den Brule FA, Waltregny D, Castronovo V. 2001. Increased expression of galectin-1 in carcinoma-associates storma predicts poor outcome in prostate carcinoma patients. J Pathol 193:80-87.
65. Wollina U, Schreiber G, Gornig M, Feldrappe S, Burchert M, Gabius HJ. 1999. Sertoli cell expression of galectin-1 and -3 and accessible binding sites in normal human testis and Sertoli cell only-syndrome. Histol Histopathol 14:779-784.
66. Xu XC, el-Naggar AK, Lotan R. 1995. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 147:815-822.
67. Yamaoka A, Kuwabara I, Frigeri LG, Liu FT. 1995. A human lectin, galectin-3 (epsilon bp/Mac-2), stimulates superoxide production by neutrophils. J Immunol 154: 3479-3487.
68. Yang RY, Hsu DK, Liu FT. 1996. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 93:6737-6742.
69. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A. 2002. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 277: 6852-6857.
70. Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, Marshall FF, Neish AS. 2001. Expression profiling of renal epithelial neoplasms. Am J Pathol 158:1639-1651.
71. Yu F, Finley RL, Jr., Raz A, Kim HR. 2002. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 277: 15819-15827.
72. Zhou Q, Cummings RD. 1993. L-14 lectin recognition of laminin and its promotion of in vitro cell adhesion. Arch Biochem Biophys 300:6-17.